TRVI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Trevi Therapeutics Inc (TRVI) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong bullish momentum, positive analyst sentiment with raised price targets, and a favorable options sentiment. Despite the RSI indicating overbought conditions, the long-term growth potential and extended cash runway into 2030 make it a compelling investment opportunity.
The technical indicators show a strong bullish trend. The MACD is positive and expanding, the RSI is at 90.389 (indicating overbought conditions), and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock has broken through key resistance levels, with R2 at 17.833 being the next target.
Analysts have raised price targets significantly (e.g., Stifel to $30, Clear Street to $
and maintain Buy ratings.
The company's key opinion leader event has strengthened confidence in Haduvio's potential to address the chronic-cough market.
Extended cash runway into 2030 provides financial stability.
RSI indicates overbought conditions, suggesting potential short-term price pullback.
No significant hedge fund or insider trading trends to support additional momentum.
No financial data available for assessment. However, the company has extended its cash runway into 2030, indicating strong financial planning.
Analysts are highly bullish on TRVI, with multiple Buy ratings and significant price target increases. Stifel raised the target to $30, Clear Street to $29, and Morgan Stanley to $20.
